Fatigue Occurs in ~50 Percent With Chronic Plaque Psoriasis

Share this content:
Fatigue Occurs in ~50 Percent With Chronic Plaque Psoriasis
Fatigue Occurs in ~50 Percent With Chronic Plaque Psoriasis

TUESDAY, Feb. 14, 2017 (HealthDay News) -- About half of patients with chronic plaque psoriasis have fatigue, according to a study published online Feb. 9 in the British Journal of Dermatology.

Inger Marie Skoie, from Stavanger University Hospital in Norway, and colleagues evaluated the prevalence and degree of fatigue among patients with chronic plaque psoriasis. Fatigue severity was assessed in 84 patients and 84 healthy controls using three generic fatigue instruments: fatigue Visual Analogue Scale (fVAS), the Fatigue Severity Scale (FSS), and the Short Form 36 (SF-36) vitality scale.

The researchers found that the median fVAS scores were 51 and 11, FSS scores were 4 and 1.6, and SF-36 vitality scores were 43 and 73, respectively, for patients and healthy control subjects. Among patients versus healthy subjects, the rates of clinically important fatigue were 51 versus 4 percent (fVAS), 52 versus 4 percent (FSS), and 42 versus 2 percent (SF-36) (all P < 0.001). In univariate, but not multivariate, analysis, fatigue was associated with the Dermatology Life Quality Index, but not with Psoriasis Area and Severity Index scores.

"A better understanding of the link between psoriasis and fatigue could promote the development of better care and self-management options for these patients, and possibly lay the foundation for more effective therapeutic approaches in the future," the authors write.

One author disclosed financial ties to Pfizer.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »